,13 In a cohort of multiple myeloma patients, NT-proBNP ≥300 ng/L was an indicator for overall survival and the authors suggested to incorporate NT-proBNP in determining the frailty of patients diagnosed with multiple myeloma.14 This evidence concerns the gene NPPB and AL amyloidosis.